Royalty Pharma Plc

As of November 14, 2025, Royalty Pharma Plc is fairly valued with a P/E ratio of 11 and has outperformed the S&P 500 year-to-date, but its long-term returns over 3 and 5 years have been significantly lower, suggesting a cautious approach for potential investors.

As of November 14, 2025, Royalty Pharma Plc is fairly valued with a P/E ratio of 11, offering better value than its peer Incyte Corp., but long-term investors should exercise caution due to its historical underperformance compared to the S&P 500.

As of October 31, 2025, Royalty Pharma Plc shows a bullish technical trend, supported by daily moving averages and monthly indicators, despite some short-term weakness indicated by weekly metrics, while outperforming the S&P 500 in recent periods but underperforming over the longer term.

As of October 31, 2025, Royalty Pharma Plc shows a bullish technical trend, supported by daily moving averages and monthly indicators, despite mixed weekly signals, and has outperformed the S&P 500 in the short term but underperformed over longer periods.

As of October 24, 2025, Royalty Pharma Plc shows a bullish technical trend, supported by daily moving averages and monthly indicators, despite mixed signals from weekly metrics, and it has significantly outperformed the S&P 500 year-to-date and over the past year.

As of October 24, 2025, Royalty Pharma Plc shows a bullish trend supported by daily moving averages and monthly indicators, despite some short-term weakness indicated by weekly metrics, and it has significantly outperformed the S&P 500 year-to-date and over the past year.

As of October 24, 2025, Royalty Pharma Plc's technical trend is bullish, supported by daily moving averages and monthly indicators, despite mixed signals from weekly metrics, and it has outperformed the S&P 500 with a year-to-date return of 46.06% compared to 15.47%.

As of September 12, 2025, Royalty Pharma Plc's technical trend is mildly bullish, with mixed signals from indicators, while it has underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of May 8, 2025, Royalty Pharma Plc is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 11, a Price to Book Value of 2.84, and a PEG ratio of 0.08, while outperforming the S&P 500 with a year-to-date return of 38.77%.

As of June 11, 2025, Royalty Pharma Plc's technical trend has shifted to bullish, supported by strong indicators like a bullish MACD and Bollinger Bands, despite a mildly bearish weekly KST, with the stock recently hitting a new 52-week high.

As of March 2022, the management team of Royalty Pharma Plc includes Chairman and CEO Pablo Legorreta, Vice Chairman Christopher Hite, Directors M. Germano Giuliani and Rory Riggs, and Independent Directors Bonnie Bassler, Errol De Souza, and Catherine Engelbert. They oversee the company's strategic direction and operations.

Royalty Pharma Plc invests in late-stage biopharmaceutical products and operates in the mid-cap market, with recent net sales of $568 million and a net profit of $433 million. The company has a market cap of approximately $19.43 billion, a P/E ratio of 11.00, and a dividend yield of 2.66%.

As of Jun 18, Royalty Pharma Plc has a market capitalization of 19,432.75 million, with net sales of 2,264.21 million and net profit of 1,768.17 million over the latest four quarters. Shareholder's funds are 6,946.58 million, and total assets amount to 18,222.72 million.